Neurizon Therapeutics Limited has released a press release.
Neurizon to present Q1 FY2026 Results
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Australian Patent Granted for NUZ-001
- FDA Lifts Clinical Hold on NUZ-001
- Neurizon Raises $5m via Institutional Placement
- R&D Tax Incentive Advance & Overseas Finding Approval
- Appendix 4E and 2025 Annual Report
Later from Neurizon Therapeutics
- Elanco executive appointed as Neurizon's Board Observer
- Neurizon Completes GMP Tablet Registration Batches
- FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
- Trading Halt
- Equity Raising Presentation
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics